Zealand Pharma Completes Enrollment in Phase 3 Trial of Dasiglucagon in Children with Congenital Hyperinsulinism (CHI)
Zealand Pharma Company announcement – No. 4 / 2022 Zealand Pharma Completes Enrollment in Phase 3 Trialof Dasiglucagon in Childrenwith Congenital Hyperinsulinism(CHI) Top-line results expected in...